C2 PHARMA
C2 PHARMA is a privately-held pharmaceutical group that manufactures and distributes niche ophthalmic and cardiac active pharmaceutical ingredients (APIs) via a virtual CMO network, serving approximately 200 pharmaceutical companies globally through direct sales and multi-jurisdiction regulatory filings.
- Company typePrivate
- Founded2014
- HeadquartersCork, Ireland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What C2 PHARMA does
C2 PHARMA is a privately-held pharmaceutical group established in 2014, headquartered in Cork, Ireland with its primary operating entity in Luxembourg. The company manufactures and distributes active pharmaceutical ingredients (APIs) and complex chemical compounds derived from natural (phytochemical) and synthetic origins, specializing in ophthalmic and niche APIs that are difficult to manufacture or face supply chain disruptions. Its 17-product portfolio includes ophthalmic APIs (atropine sulfate, bimatoprost, brimonidine tartrate, cyclopentolate hydrochloride, dorzolamide hydrochloride, homatropine hydrobromide, latanoprost, naphazoline hydrochloride, naphazoline nitrate, oxybuprocaine hydrochloride, pilocarpine hydrochloride, pilocarpine nitrate, timolol maleate, tropicamide) and cardiac APIs (digoxin, digoxin micronized), with multiple products on the WHO List of Essential Medicines.
The company's core technology is a virtual manufacturing model that coordinates a curated network of contract manufacturing organizations (CMOs) including Laurus Labs in India, Nobilus Ent in Poland, SMS Lifesciences, and Anidro do Brasil, with proprietary quality oversight including annual audits and quality assurance agreements. This model is supplemented by wholly-owned affiliates: ASM Research Chemicals GmbH (Hannover) for R&D-scale synthesis of complex organic molecules and PNA monomers, and Logistics4Pharma for GDP-compliant cold chain storage and global air freight. C2 PHARMA holds an extensive portfolio of regulatory filings across the US (US-DMF), Europe (CEP), China (C-DMF), Taiwan (T-DMF), South Korea (K-DMF), Brazil, and Mexico, with several CEP approvals noted as first or second of their kind.
C2 PHARMA generates revenue through direct sales of APIs and drug products to approximately 200 pharmaceutical companies globally, including top big pharma firms, with a sales-led go-to-market focused on ophthalmic and niche API buyers. Additional revenue streams include API lifecycle management services (acquiring and managing non-core or difficult-to-manufacture APIs on behalf of pharmaceutical clients) and affiliated cold chain logistics services. Pricing is quote-based and not publicly disclosed. The company is wholly owned by founder and CEO Andrew Badrot, with no disclosed institutional venture capital or private equity backing, and operates through legal entities in Ireland, Luxembourg, the United States, Germany, and India.
C2 PHARMA firmographics
Firmographics- Name
- C2 PHARMA
- Legal name
- C-squared PHARMA Limited / C-squared PHARMA S.à r.l.
- Website
- https://c2pharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- C2 PHARMA is a privately-held pharmaceutical group that manufactures and distributes niche ophthalmic and cardiac active pharmaceutical ingredients (APIs) via a virtual CMO network, serving approximately 200 pharmaceutical companies globally through direct sales and multi-jurisdiction regulatory filings.
- Ownership category
- akta.pro rank
C2 PHARMA industry classification
Industry- Product category
- Active Pharmaceutical Ingredients
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Small-Molecule API Commercial Manufacturing (HLAGAHAB)
- akta.pro secondary industries
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Specialty Pharmaceutical Distributors (HLAIAJAB), Pharmaceutical & Life Sciences Warehousing (GDP-Compliant) (TLAIACAD)
Keywords
Where C2 PHARMA is headquartered
LocationHeadquarters
- HQ city
- Cork
- HQ country
- Ireland
- HQ region
- Europe
Offices6 records
Markets served
C2 PHARMA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Others
Revenue model
- API Manufacturing and Distribution: Manufacturing and distribution of active pharmaceutical ingredients (APIs) including ophthalmic APIs (atropine sulfate, bimatoprost, brimonidine tartrate, cyclopentolate hydrochloride, dorzolamide hydrochloride, homatropine hydrobromide, latanoprost, naphazoline hydrochloride, naphazoline nitrate, oxybuprocaine hydrochloride, pilocarpine hydrochloride, pilocarpine nitrate, timolol maleate, tropicamide) and cardiac APIs (digoxin, digoxin micronized). Direct sales to approximately 200 pharmaceutical companies globally.
- API Lifecycle Management Services: Services to streamline pharmaceutical companies' product portfolios by acquiring and managing non-core, difficult-to-manufacture, or challenging-to-distribute APIs and drug products.
- Cold Chain Logistics: Customized cold chain and GDP-compliant transport and storage solutions through affiliate Logistics4Pharma.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
C2 PHARMA product offering
Product offeringCore offering
C2 PHARMA manufactures and distributes Active Pharmaceutical Ingredients (APIs) and complex chemical compounds from natural and synthetic origins. The company operates a virtual manufacturing model combining contract manufacturing organizations (CMOs) with proprietary quality oversight, specializing in niche and ophthalmic APIs such as atropine sulfate, bimatoprost, digoxin, latanoprost, pilocarpine, and tropicamide for approximately 200 pharmaceutical customers globally. The company also offers API lifecycle management services and GDP-compliant cold chain logistics through affiliate Logistics4Pharma.
Product overview
C2 PHARMA is a pharmaceutical group established in 2014 that manufactures and distributes active pharmaceutical ingredients (APIs) and complex chemical compounds obtained from natural and synthetic origins. The company positions itself as a global leader in ophthalmic and niche APIs, offering 17 distinct API products including Bimatoprost, Brimonidine Tartrate, Cyclopentolate Hydrochloride, Digoxin, Dorzolamide Hydrochloride, Homatropine Hydrobromide, Homatropine Methylbromide, Latanoprost, Naphazoline Hydrochloride, Naphazoline Nitrate, Oxybuprocaine Hydrochloride, Pilocarpine Hydrochloride, Pilocarpine Nitrate, Timolol Maleate, and Tropicamide. The product portfolio spans ophthalmic APIs for glaucoma treatment and eye diagnostics, cardiac glycosides for heart conditions, and topical decongestants. Services include API Manufacturing and Distribution, API Lifecycle Management, and Pharma Logistics through affiliated company Logistics4Pharma offering GDP-compliant cold-chain transport and storage. The company maintains a direct sales presence across approximately 200 pharmaceutical customers globally including top pharmaceutical companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Atropine Sulfate A naturally occurring phytochemical alkaloid originally identified in Atropa belladonna, used as an antidote for cholinergic drug and organophosphate poisoning, and for ophthalmic formulations as a cycloplegic pre-diagnostic agent and treatment for refractive and accommodative amblyopia. Sold to pharmaceutical manufacturers.
- Bimatoprost A synthetic amide analogue (prostamide) of prostaglandin F2α, used as first-line treatment for glaucoma in European Glaucoma Society guidelines, as 0.03% ophthalmic solution for ocular hypertension and glaucoma, and for eyelash hypotrichosis. Sold to ophthalmic pharmaceutical manufacturers.
- Brimonidine Tartrate A synthetic, highly selective third generation α2-adrenergic agonist used to reduce intraocular pressure through dual mechanism of reducing aqueous humour production and increasing uveoscleral outflow, approved in more than 50 countries. Sold to ophthalmic pharmaceutical manufacturers.
- Cyclopentolate Hydrochloride A synthetic muscarinic receptor antagonist developed in the 1950s, used as first-choice drug for cycloplegic refraction and diagnostic pupil dilation in patients of all ages, on WHO List of Essential Medicines. Sold to ophthalmic pharmaceutical manufacturers.
- Digoxin A cardiac glycoside extracted from Digitalis lanata leaves, used chronically in therapy of cardiac arrhythmias especially atrial fibrillation and heart failure, on WHO List of Essential Medicines. Sold to cardiovascular pharmaceutical manufacturers.
- Digoxin Micronized A micronized grade of cardiac glycoside extracted from Digitalis lanata leaves, developed to meet stringent specifications for particle size distribution less than 10 μm, used for cardiac arrhythmias and heart failure treatment. Sold to cardiovascular pharmaceutical manufacturers.
- Dorzolamide Hydrochloride A topical carbonic anhydrase inhibitor (CAI) belonging to sulfonamide derivatives, selectively inhibits carbonic anhydrase II, used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Sold to ophthalmic pharmaceutical manufacturers.
- Homatropine Hydrobromide A synthetic analogue of atropine prepared by esterification of mandelic acid with 3α-tropine, used as 2% or 5% ophthalmic solution to induce mydriasis and cycloplegia prior to retinoscopy, with effect 10 times weaker than atropine. Sold to ophthalmic pharmaceutical manufacturers.
- Homatropine Methylbromide A synthetic analog of atropine belonging to antimuscarinics, used to treat duodenal or stomach ulcers and intestinal problems, may be used to prevent nausea, vomiting, and motion sickness, and as sub-therapeutic amount in opioid formulations. Sold to pharmaceutical manufacturers.
- Latanoprost A rationally designed synthetic ester prodrug analogue of prostaglandin F2α (PGF2α), on WHO List of Essential Medicines and top 100 most commonly prescribed medications in the US, used for reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension. Sold to ophthalmic pharmaceutical manufacturers.
- Naphazoline Hydrochloride A white crystalline sympathomimetic amine compound, patented in 1934 and used primarily to relieve allergy symptoms and as decongestant, with CNS stimulant and blood vessel constrictor properties for reducing redness in minor eye irritations. Sold to pharmaceutical manufacturers.
- Naphazoline Nitrate A white crystalline powder developed in 1942 as nasal formulation for congestion, primarily used as topical nasal decongestant but also included in ophthalmic solutions to alleviate ocular redness and irritation. Sold to pharmaceutical manufacturers.
- Oxybuprocaine Hydrochloride A synthetic local anesthetic also known as benoxinate, first described in 1950, used in 0.4% ophthalmic solution for short ocular diagnostic and minor surgical procedures, with anesthetic activity ten times that of cocaine. Sold to ophthalmic pharmaceutical manufacturers.
- Pilocarpine Hydrochloride An agonist of muscarinic type cholinergic receptors, isolated from jaborandi leaves, used in eye drops for glaucoma treatment and as oral tablets for dry mouth and eyes caused by Sjögren's syndrome and salivary gland hypofunction from radiotherapy. Sold to ophthalmic pharmaceutical manufacturers.
- Pilocarpine Nitrate An agonist of muscarinic type cholinergic receptors derived from Pilocarpus microphyllus (Maranham Jaborandi), exclusive distribution by C2 PHARMA from Anidro do Brasil, used for chronic glaucoma treatment and to increase sweat secretion by iontophoresis in cystic fibrosis diagnostic devices. Sold to ophthalmic pharmaceutical manufacturers.
- Timolol Maleate A non-selective beta-adrenergic antagonist (β1 and β2) patented in 1978, used topically to reduce intraocular pressure in open-angle glaucoma or ocular hypertension, and systemically for hypertension, myocardial infarction, arrhythmias and migraine prophylaxis. Sold to ophthalmic pharmaceutical manufacturers.
- Tropicamide A fully synthetic non-selective muscarinic antagonist developed in the 1950s, on WHO List of Essential Medicines, used as 0.5% and 1% topical ophthalmic solution for mydriasis and cycloplegia in diagnostic procedures, and reported as diagnostic tool in Alzheimer's disease. Sold to ophthalmic pharmaceutical manufacturers.
- API Lifecycle Management Services Comprehensive end-to-end management of APIs from development through commercial supply, including regulatory filings, manufacturing oversight, and quality control. Services streamline pharmaceutical companies' product portfolios by acquiring and managing non-core, difficult-to-manufacture, or challenging-to-distribute APIs and drug products. Targeted at pharmaceutical manufacturers.
- GDP-Compliant Cold Chain Logistics Customized cold chain and GDP-compliant transport and storage solutions for APIs and pharmaceutical products, supporting temperature ranges of +2 to +8°C, +15 to +25°C, and -15 to -25°C. Operates 1000 m2 warehouse near Frankfurt Airport with validated temperature-controlled vehicles and IATA license for global air freight. Targeted at pharmaceutical manufacturers requiring temperature-controlled distribution.
Companies that use C2 PHARMA
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles3 records
C2 PHARMA technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
C2 PHARMA partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered supporting, core and strategic.
- SMS LifesciencessupportingAdditional CMO partner added to strengthen manufacturing network and accelerate bringing R&D portfolio of ophthalmic products to commercial market.
- Nobilus EntcorePolish manufacturing partner for digoxin API acquired from Roche/Galenus Mannheim. C2 PHARMA is product owner; Nobilus is manufacturing partner and releasing entity. Provides parallel manufacturing for supply redundancy.
- Theracule ASstrategicStrategic partnership focused on supporting Theracule's new drug development programs for rare neurodevelopmental disorders. C2 PHARMA leads seed funding and provides GMP-compliant botanical extracts and APIs, regulatory support, and analytical sciences support through ASM Research Chemicals.
- Logistics4PharmacoreCold-chain logistics spin-off established by C2 PHARMA offering GDP-compliant transport and storage solutions for APIs and pharmaceutical products. Operates 1000 m2 warehouse near Frankfurt Airport with validated temperature-controlled vehicles and IATA license for global air freight.
- ASM Research Chemicals GmbHcoreR&D synthesis services company acquired by C2 PHARMA located in Hannover, Germany. Pioneer in synthesis of PNA (Peptide Nucleic Acid) Monomers and provides contract manufacturing for R&D-scale synthesis of complex organic molecules and impurities. Operates 600 m2 chemistry laboratory with 13 staff, 7 PhD chemists.
- Anidro do Brasil ExtraçõescoreWorld's leading manufacturer of pilocarpine, exclusive distributor relationship with C2 PHARMA. Produces pilocarpine extracted from Jaborandi plant leaves (Pilocarpus microphyllus) native to northern Brazil.
- Laurus LabscoreIndian-based API manufacturer and CMO partner. C2 PHARMA invested in dedicated digoxin manufacturing facility at Laurus Labs site in Vizag, India. Investment exceeded USD 5 million for 1800 m2 facility with annual production capacity exceeding global digoxin demand.
Scale indicators8 records
Recent moves8 records
Expansion highlights5 records
C2 PHARMA competitors and assessment
Company assessmentDirect peers
- EuroAPI: European specialty small-molecule API manufacturer spun out of Sanofi, serving branded and generic pharma with complex APIs across multiple therapeutic categories. Directly comparable to C2 PHARMA's small-molecule, multi-regulatory niche API model and customer base of top pharma companies.
- Hovione: Portugal-headquartered specialty CDMO with deep small-molecule API and ophthalmic expertise, including particle engineering for inhaled and ophthalmic dosage forms. Competes head-to-head with C2 PHARMA for complex API contracts and shares the same ophthalmic and niche-pharma customer profile.
- Cambrex (Eurofins Discovery): Specialty small-molecule API manufacturer offering process R&D, scale-up, and commercial manufacturing across multiple therapeutic categories including ophthalmology. Operates a similar asset-and-virtual hybrid API model serving global pharma customers, comparable in product portfolio breadth and regulatory complexity.
- Divi's Laboratories: India-headquartered API manufacturer and custom synthesis provider serving global generics and Big Pharma with complex small molecules. Comparable scale, generic/specialty API mix, US-DMF/CEP-heavy regulatory footprint, and ophthalmic API capabilities paralleling C2 PHARMA's commercial manufacturing model.
- Piramal Pharma Solutions: Global CDMO/API division of Piramal Pharma offering small-molecule API development, tech transfer and commercial manufacturing to branded and generic pharma. Overlaps with C2 PHARMA's virtual manufacturing strategy and global pharma customer base across ophthalmic, cardiovascular and specialty molecules.
- Laurus Labs: Indian API and formulation manufacturer that operates C2 PHARMA's dedicated digoxin facility but also sells APIs independently into global generics and Big Pharma. Overlaps in small-molecule API manufacturing, CMO services, and the same ophthalmic/contract-manufacturing competitive space.
- Johnson Matthey Health (Veranova): Specialty API/HPAPI CDMO business (now Veranova) offering complex small-molecule development and commercial manufacturing to global pharma. Comparable complexity, regulatory intensity, and customer profile to C2 PHARMA's niche-API commercial manufacturing model.
- Indena: Italy-headquartered specialist in botanical-derived APIs and phytochemical extracts for pharma, with deep sustainability and traceability programs for natural-source ingredients. Direct mirror of C2 PHARMA's phytochemical expertise (pilocarpine, digoxin/Digitalis, atropine) and plant-derived API positioning.
- PolyPeptide Group: Specialty peptide and small-molecule API manufacturer serving global pharma and ophthalmic customers with regulatory-grade peptides and complex actives. Comparable in niche positioning, regulatory depth (US-DMF, CEP) and GMP manufacturing across multiple therapeutic categories.
Broad incumbents
- Aurobindo Pharma: Large vertically integrated Indian generic manufacturer with significant ophthalmic API/formulation operations and global Big Pharma supply contracts. Competes broadly with C2 PHARMA in ophthalmic APIs but across a much wider product set and own-plant model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
C2 PHARMA social profiles
Digital presenceC2 PHARMA financial estimates
Financial estimateRevenue estimate
Valuation estimate
C2 PHARMA leadership team
Management profileNumber of profiles
Profiles9 records
C2 PHARMA subsidiaries and ownership
Company hierarchySubsidiaries1 record
C2 PHARMA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
C2 PHARMA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about C2 PHARMA
What does C2 PHARMA do?
C2 PHARMA manufactures and distributes Active Pharmaceutical Ingredients (APIs) and complex chemical compounds from natural and synthetic origins. The company operates a virtual manufacturing model combining contract manufacturing organizations (CMOs) with proprietary quality oversight, specializing in niche and ophthalmic APIs such as atropine sulfate, bimatoprost, digoxin, latanoprost, pilocarpine, and tropicamide for approximately 200 pharmaceutical customers globally. The company also offers API lifecycle management services and GDP-compliant cold chain logistics through affiliate Logistics4Pharma.
Is C2 PHARMA a public or private company?
C2 PHARMA is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was C2 PHARMA founded?
C2 PHARMA was founded in 2014. It employs 11 to 50 people.
Where is C2 PHARMA based?
C2 PHARMA is headquartered in Cork, Ireland, in the Europe region.
How does C2 PHARMA make money?
Three revenue lines are on record. API Manufacturing and Distribution is the primary driver. The others are API Lifecycle Management Services and cold Chain Logistics.
Who are C2 PHARMA's main competitors?
Direct peers on record are EuroAPI, Hovione, Cambrex (Eurofins Discovery), Divi's Laboratories, Piramal Pharma Solutions, Laurus Labs, Johnson Matthey Health (Veranova), Indena and PolyPeptide Group. Aurobindo Pharma is listed as a broad incumbent.
Does C2 PHARMA have an API?
No public API is recorded for C2 PHARMA.
What industry is C2 PHARMA in?
C2 PHARMA's product category is Active Pharmaceutical Ingredients. Its primary akta.pro industry code is HLAGAHAB, Small-Molecule API Commercial Manufacturing, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.